Breakthroughs and Challenges Await Science in 2026

As 2026 approaches, the scientific community is poised for a year marked by significant advancements and ongoing challenges. Following a tumultuous 2025, which saw both groundbreaking discoveries and a crisis of confidence in various scientific fields, key developments in physics, medicine, and environmental policy are anticipated. The landscape of science is evolving, and critical events are set to shape its future.

Major Scientific Facilities Undergo Transformations

One of the most notable shifts in 2026 will occur at the Large Hadron Collider (LHC) at CERN in Switzerland. Starting in July, the LHC will commence a four-year hiatus to facilitate substantial upgrades. This monumental particle physics facility has contributed to numerous significant discoveries, and its return as the High-Luminosity LHC in 2030 is eagerly awaited.

Meanwhile, the Brookhaven National Laboratory will also see a major transition as it prepares to shut down the Relativistic Heavy Ion Collider (RHIC). This marks the first time in 25 years that Brookhaven will be without a major particle accelerator. The shutdown aims to prepare for the upcoming Electron-Ion Collider, although detailed progress updates remain scarce.

In Illinois, Fermilab is expected to complete its new muon detector by spring 2026. Yet, uncertainty surrounds the timeline, as the laboratory has not confirmed whether the project will meet its deadline.

Advancements in Quantum Computing and Medicine

2025 proved to be a pivotal year for quantum computing, with major players like IBM, Google, and AWS advancing their hardware capabilities. This momentum is expected to continue into 2026, as smaller startups join the race. The latest models from Quantinuum and IBM, named Helios and Nighthawk respectively, will soon be available for researchers, potentially unlocking new avenues in quantum technology.

In the realm of medicine, 2026 is set to deliver promising advancements. Long-awaited data from a Phase III trial of a new tuberculosis vaccine is expected early in the year, coming in ahead of schedule. Additionally, the first clinical trial of pig-to-human organ transplantation began in late 2025, with results anticipated soon. The potential approval of Takeda Pharmaceuticals‘ innovative treatment for narcolepsy, named oveporexton, is also on the horizon.

The trend of weight-loss medications will likely continue its momentum into 2026. Eli Lilly is preparing to submit a new GLP-1 pill for obesity, named orforglipron, for FDA approval. Concurrently, Novo Nordisk is expected to launch its next-generation obesity drug, CargiSema, a combination of cagrilintide and semaglutide, after seeking approval early in the year. These developments could lead to significant price reductions for consumers, driven by heightened competition and government subsidies.

Environmental policy is also under scrutiny as the NOAA and the Fish and Wildlife Service propose changes to the Endangered Species Act. The revisions could limit protections to endangered species themselves, rather than their habitats, potentially easing human construction in critical areas. Such regulatory rollbacks, alongside actions taken by the current administration to diminish the role of the Federal Emergency Management Agency (FEMA), raise concerns about the United States’ preparedness for future climate challenges.

Global Scientific Endeavors and Gene Editing Breakthroughs

In 2026, China will embark on its next Five-Year Plan, which includes ambitious projects such as the operationalization of small modular nuclear reactors. These reactors promise to provide energy to remote regions, showcasing China’s commitment to innovative energy solutions. Additionally, China’s drilling ship, Meng Xiang, is set to undertake its first scientific mission, aiming to drill approximately 4.35 miles (7 kilometers) into the Earth’s crust to collect valuable geological samples.

Gene editing is also on the brink of mainstream acceptance. The first clinical trial results for a gene-editing technique targeting lipid disorders were reported in November 2025. The success of KJ Muldoon, a baby who received a life-saving CRISPR-based therapy, emphasizes the potential of such treatments. With several CRISPR therapies entering clinical trials in 2026, significant investments from major pharmaceutical companies indicate a robust future for gene editing technologies.

As the scientific community navigates through a landscape of opportunities and obstacles, 2026 is positioned to be a pivotal year. The advancements in technology and medicine, coupled with the challenges posed by regulatory changes and environmental concerns, will define the trajectory of science for years to come.